Siemens Healthineers releases CN-3000, CN-6000 hemostasis systems
Sept. 16, 2026—Siemens Healthineers has released the CN-3000 and CN-6000 automated hemostasis analyzers for mid- and high-volume laboratories in the United States.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
ARUP study underscores value of atypical cfDNA results
Sept. 10, 2026—A research study by ARUP Laboratories clarifies the clinical value of atypical findings from prenatal cell-free DNA screening and their impact on pregnancy outcomes.
FDA clears NanoZoomer S20MD, S540MD slide scanner systems
Sept. 8, 2026—Hamamatsu Photonics has received FDA 510(k) clearance for the NanoZoomer S20MD and S540MD slide scanner systems.
FDA approves targeted therapy for metastatic pancreatic cancer
Aug. 26, 2026—The Food and Drug Administration today approved daraxonrasib (Rasonque, Revolution Medicines) for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
FDA clears the C2N Diagnostics PrecivityAD2 test
Aug. 25, 2026—The FDA has cleared C2N Diagnostics’ PrecivityAD2 test, indicated for use in adults aged 40 years and older who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer’s disease or other forms of cognitive decline.
Roche gets FDA clearance for Elecsys pTau217
Aug. 24, 2026—The Food and Drug Administration has cleared Roche’s Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test, to aid in identifying amyloid pathology associated with Alzheimer’s disease in people 55 years and older with signs, symptoms, or complaints of cognitive decline.
PathVisions26: Connecting Innovation with Purpose
Aug. 21, 2026—The Digital Pathology Association’s annual meeting, Pathology Visions 2026, is taking place October 16–18 in San Diego.
FDA authorizes Aletta robotic blood draw device
Aug. 20, 2026—The U.S. Food and Drug Administration authorized Vitestro’s Aletta, the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention.
Pillar, LC-SCRUM-Asia, LSI Medience partner on liquid biopsy screening
Aug. 19, 2026—Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience Corp. are collaborating to support the genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan.
Zepto awarded NIAID contract valued at up to $8.9 million
Aug. 12, 2026—Zepto Life Technology has been awarded a contract valued at up to $8.9 million from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the company’s plasma cell-free DNA liquid biopsy platform for invasive fungal infections.